S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LMAO
LMF Acquisition Opportunities
$12.35
$10.83
$5.72
$22.00
$140.05M-0.0150,946 shs560,236 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.80
$1.09
$0.76
$1.85
$38.55M1.63247,819 shs116,108 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$3.80
-0.8%
$3.89
$1.03
$5.07
$114.80M2.44180,665 shs48,572 shs
TELA Bio, Inc. stock logo
TELA
TELA Bio
$4.75
-7.8%
$5.93
$4.23
$11.26
$126.94M0.95189,685 shs119,454 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LMAO
LMF Acquisition Opportunities
0.00%0.00%0.00%0.00%0.00%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-0.44%-1.55%-28.24%-45.07%-50.22%
Neuronetics, Inc. stock logo
STIM
Neuronetics
-0.78%-12.04%-11.63%+14.46%+74.31%
TELA Bio, Inc. stock logo
TELA
TELA Bio
-7.77%-3.46%-13.79%-30.30%-48.54%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LMAO
LMF Acquisition Opportunities
N/AN/AN/AN/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
1.8945 of 5 stars
3.53.00.00.02.61.70.0
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.8763 of 5 stars
3.33.00.00.02.11.70.6
TELA Bio, Inc. stock logo
TELA
TELA Bio
1.6792 of 5 stars
3.52.00.00.01.81.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LMAO
LMF Acquisition Opportunities
N/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
3.00
Buy$2.75245.26% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.50
Moderate Buy$8.00110.53% Upside
TELA Bio, Inc. stock logo
TELA
TELA Bio
3.00
Buy$13.67187.72% Upside

Current Analyst Ratings

Latest STIM, LMAO, TELA, and LUCD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.50
3/27/2024
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$3.80 ➝ $3.00
3/27/2024
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.50
3/26/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/22/2024
TELA Bio, Inc. stock logo
TELA
TELA Bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
3/22/2024
TELA Bio, Inc. stock logo
TELA
TELA Bio
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $12.00
3/6/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LMAO
LMF Acquisition Opportunities
N/AN/AN/AN/A($0.93) per shareN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$2.43M15.81N/AN/A($0.47) per share-1.69
Neuronetics, Inc. stock logo
STIM
Neuronetics
$71.35M1.60N/AN/A$1.18 per share3.22
TELA Bio, Inc. stock logo
TELA
TELA Bio
$58.45M2.00N/AN/A$0.77 per share6.17

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LMAO
LMF Acquisition Opportunities
$80KN/A0.00N/AN/A-44.29%3.70%N/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$52.67M-$1.27N/AN/A-2,169.07%-901.79%-121.11%5/20/2024 (Estimated)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$1.07N/AN/AN/A-42.31%-72.76%-29.25%5/14/2024 (Estimated)
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$46.66M-$2.07N/AN/AN/A-79.83%-201.62%-58.60%5/9/2024 (Estimated)

Latest STIM, LMAO, TELA, and LUCD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/A-$0.26-$0.26-$0.26N/A$1.04 million    
3/21/2024Q4 2023
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$0.44-$0.53-$0.09-$0.53$16.65 million$17.00 million
3/5/202412/31/2023
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LMAO
LMF Acquisition Opportunities
N/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LMAO
LMF Acquisition Opportunities
N/A
14.35
14.35
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/A
0.75
0.74
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.73
4.73
4.33
TELA Bio, Inc. stock logo
TELA
TELA Bio
2.15
4.23
3.45

Ownership

Institutional Ownership

CompanyInstitutional Ownership
LMAO
LMF Acquisition Opportunities
85.03%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
74.01%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%
TELA Bio, Inc. stock logo
TELA
TELA Bio
94.35%

Insider Ownership

CompanyInsider Ownership
LMAO
LMF Acquisition Opportunities
N/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
4.80%
Neuronetics, Inc. stock logo
STIM
Neuronetics
7.30%
TELA Bio, Inc. stock logo
TELA
TELA Bio
5.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
LMAO
LMF Acquisition Opportunities
N/A11.34 millionN/ANot Optionable
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
7048.24 million45.93 millionNo Data
Neuronetics, Inc. stock logo
STIM
Neuronetics
20329.98 million27.79 millionOptionable
TELA Bio, Inc. stock logo
TELA
TELA Bio
22724.65 million23.25 millionOptionable

STIM, LMAO, TELA, and LUCD Headlines

SourceHeadline
TELA Bio Launches Innovative Hernia Repair Device in the U.S. MarketTELA Bio Launches Innovative Hernia Repair Device in the U.S. Market
msn.com - April 17 at 9:16 AM
TELA Bio launches OviTex IHR for inguinal hernia repair in USTELA Bio launches OviTex IHR for inguinal hernia repair in US
msn.com - April 16 at 5:32 PM
TELA Bio announces US launch OviTex IHR for use in laparoscopic and robotic-assisted inguinal hernia repairTELA Bio announces US launch OviTex IHR for use in laparoscopic and robotic-assisted inguinal hernia repair
pharmabiz.com - April 16 at 7:29 AM
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia ProceduresTELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
globenewswire.com - April 15 at 7:00 AM
MDXG: Legal AvenuesMDXG: Legal Avenues
finance.yahoo.com - April 11 at 1:10 PM
TELA Bio Appoints Esteemed Surgeon Dr. Howard N. Langstein as Vice President of Medical AffairsTELA Bio Appoints Esteemed Surgeon Dr. Howard N. Langstein as Vice President of Medical Affairs
msn.com - April 10 at 6:58 AM
TELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon StrategyTELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
finanznachrichten.de - April 8 at 4:17 PM
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon StrategyTELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
globenewswire.com - April 8 at 7:00 AM
TELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024TELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024
msn.com - March 25 at 8:23 AM
Analysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year ResultsAnalysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year Results
finance.yahoo.com - March 24 at 5:22 PM
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call TranscriptTELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 23 at 11:14 PM
TELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)TELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)
finance.yahoo.com - March 23 at 8:39 AM
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia SurgeryTELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
stockhouse.com - March 22 at 5:36 PM
TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call TranscriptTELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 22 at 5:36 PM
JMP Securities Reiterates Market Outperform Rating for TELA Bio (NASDAQ:TELA)JMP Securities Reiterates Market Outperform Rating for TELA Bio (NASDAQ:TELA)
marketbeat.com - March 22 at 2:10 PM
Piper Sandler Trims TELA Bio (NASDAQ:TELA) Target Price to $12.00Piper Sandler Trims TELA Bio (NASDAQ:TELA) Target Price to $12.00
marketbeat.com - March 22 at 10:25 AM
Q4 2023 TELA Bio Inc Earnings CallQ4 2023 TELA Bio Inc Earnings Call
finance.yahoo.com - March 22 at 7:36 AM
Recap: TELA Bio Q4 EarningsRecap: TELA Bio Q4 Earnings
benzinga.com - March 21 at 9:14 PM
TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023
msn.com - March 21 at 9:14 PM
TELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023TELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023
finance.yahoo.com - March 21 at 9:14 PM
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue EstimatesTELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
zacks.com - March 21 at 6:31 PM
Strategic Divestiture and Innovative Product Launch Fuel Buy Rating for TELA BioStrategic Divestiture and Innovative Product Launch Fuel Buy Rating for TELA Bio
markets.businessinsider.com - March 21 at 4:13 PM
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial ResultsTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
finance.yahoo.com - March 21 at 4:13 PM
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial ResultsTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
globenewswire.com - March 21 at 4:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

LMF Acquisition Opportunities

NASDAQ:LMAO
LMF Acquisition Opportunities, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Tampa, Florida.
Lucid Diagnostics logo

Lucid Diagnostics

NASDAQ:LUCD
Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Neuronetics logo

Neuronetics

NASDAQ:STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
TELA Bio logo

TELA Bio

NASDAQ:TELA
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.